Pharma Giant J&J Brings In $502 Million In Quarterly Covid Vaccine Sales

Johnson & Johnson (JNJ) reported $502 million in Covid vaccine sales on Tuesday and beat Wall Street’s profit forecasts, leading JNJ stock to pop.


Sales of the Covid vaccine came in lighter than expected, Edward Jones analyst Ashtyn Evans said in a report to clients. But the Dow Jones company still expects $2.5 billion in sales of the one-shot vaccine this year. The news comes shortly after a Food and Drug Administration panel of experts endorsed J&J’s Covid booster shot at least two months after the first dose.

Total sales narrowly lagged forecasts. Evans cited the low Covid vaccine sales and the delta variant’s impact on elective surgical procedures. Some patients are still delaying elective procedures to avoid the possibility of a Covid exposure.

But “growth continues to be driven by strong sales growth in the pharmaceutical segment, particularly from cancer drugs and infectious disease products,” Evans said. She kept her buy rating on JNJ stock.

JNJ Stock: Earnings Beat, Sales Light

On the stock market today, JNJ stock jumped 2.3% to 163.87.

During the third quarter, Johnson & Johnson earned $2.60 per share on $23.34 billion in sales. Profit beat the forecast of analysts polled by FactSet for $2.35 a share. But sales were slightly below analysts’ call for $23.64 billion.

On a year-over-year basis, sales increased 10.7% and earnings rose 18.2%.

The strongest growth came from Johnson & Johnson’s infectious diseases portfolio, which includes the Covid vaccine. Overall, sales surged 60.6% on a strict as-reported basis to $1.39 billion. Revenue from cancer drugs advanced 17.1% to $3.67 billion.

But the medical devices segment struggled. Overall, sales increased 8% to $6.64 billion with the best growth coming from interventional solutions. But revenue from the orthopedic segment crept up just a fraction. Sales of spine, sports and other orthopedics sank 5.3% to $705 million.

Covid Vaccine Guidance Reiterated

For the year, Johnson & Johnson raised the low end of its sales outlook. Now, the company expects $91.6 billion to $92.1 billion in full-year sales. In addition, J&J called for $2.5 billion in sales from its Covid vaccine. The company also expects to earn $9.77-$9.82 per share, up from its prior guidance for $9.60-$9.70 a share.

JNJ stock analysts called for Johnson & Johnson to earn $9.71 a share on $94.36 billion in sales.

The earnings report sent shares closer to their 50-day moving average. JNJ stock is currently forming a flat base with a buy point at 180.02, according to

Follow Allison Gatlin on Twitter at @IBD_AGatlin.


Ionis Stock Collapses On Another ‘Misstep’ As Biogen-Partnered ALS Drug Flops

The Next Challenge For Covid Stocks Is Also A Cash Cow For These Companies

Want To Get Quick Profits And Avoid Big Losses? Try SwingTrader

Best Growth Stocks To Buy And Watch: See Updates To IBD Stock Lists

Find Today’s Best Growth Stocks To Watch With IBD 50

Most Related Links :
nativenewspost Governmental News Finance News

Source link

Back to top button